Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis

Background Eosinophilic esophagitis (EoE) is a chronic allergic disease with esophageal symptoms and intraepithelial eosinophil infiltration. Effects of potassium-competitive acid blockers (P-CABs) on EoE have not been elucidated. We aimed to examine and compare the effects of P-CABs and PPIs on sym...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Esophagus : official journal of the Japan Esophageal Society 2021-04, Vol.18 (2), p.372-379
Hauptverfasser: Kuzumoto, Takuya, Tanaka, Fumio, Sawada, Akinari, Nadatani, Yuji, Otani, Koji, Hosomi, Shuhei, Kamata, Noriko, Taira, Koichi, Nagami, Yasuaki, Tanigawa, Tetsuya, Watanabe, Toshio, Fujiwara, Yasuhiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Eosinophilic esophagitis (EoE) is a chronic allergic disease with esophageal symptoms and intraepithelial eosinophil infiltration. Effects of potassium-competitive acid blockers (P-CABs) on EoE have not been elucidated. We aimed to examine and compare the effects of P-CABs and PPIs on symptomatic, endoscopic, and histological responses of patients with EoE. Methods We analyzed 118 EoE patients who received PPI or P-CAB therapy with rabeprazole 10 mg (RPZ10, N  = 22), rabeprazole 20 mg (RPZ20, N  = 34), esomeprazole 20 mg (EPZ20, N  = 25), or vonoprazan 20 mg (VPZ20, N  = 33). We evaluated symptomatic responses by classifying the patients into three groups: complete relief, partial relief, and no change. Endoscopic responses were evaluated using the endoscopic reference score (EREFS) following PPI or P-CAB therapy. Histological responses were evaluated by determining eosinophil counts in esophageal biopsy samples and classifying the patients into two groups: complete remission [0/1 eosinophil/high-power field (eos/HPF)] and remission (
ISSN:1612-9059
1612-9067
DOI:10.1007/s10388-020-00783-0